Vaxova Drugs Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 04-12-2024
- Paid Up Capital ₹ 7.50 M
as on 04-12-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.21 Cr
as on 04-12-2024
- Revenue 128.50%
(FY 2022)
- Profit 97.92%
(FY 2022)
- Ebitda 276.60%
(FY 2022)
- Net Worth 96.18%
(FY 2022)
- Total Assets 90.92%
(FY 2022)
About Vaxova Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.50 M.
The company currently has active open charges totaling ₹2.21 Cr.
Ankush Kumar, Narender, and Vashist Sandhu serve as directors at the Company.
- CIN/LLPIN
U74993HR2018PTC073704
- Company No.
073704
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Vaxova Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vashist Sandhu  | Director | 06-Mar-2021 | Current |
| Ankush Kumar | Director | 20-Apr-2018 | Current |
| Narender | Director | 06-Mar-2021 | Current |
Financial Performance of Vaxova Drugs.
Vaxova Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 128.5% increase. The company also saw a substantial improvement in profitability, with a 97.92% increase in profit. The company's net worth Soared by an impressive increase of 96.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vaxova Drugs?
Unlock access to Vaxova Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Alfavision Biotech Private LimitedActive 4 years 2 monthsAnkush Kumar, Narender and 1 more are mutual person
- Vaxova Life Sciences Private LimitedActive 3 years 3 months
Ankush Kumar, Narender and 1 more are mutual person
Charges (Loans)
₹22.14 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 2.00 Cr
- Hdfc Bank Limited : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Oct 2024 | Canara Bank | ₹2.00 Cr | Open |
| 21 Oct 2020 | Hdfc Bank Limited | ₹2.14 M | Open |
How Many Employees Work at Vaxova Drugs?
Unlock and access historical data on people associated with Vaxova Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vaxova Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vaxova Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
